BeStock  
Stocks › Biotechnology › RIGL

Rigel Pharmaceuticals RIGL

US equityMarket cap rank #3339Biotechnology
$40.09 −$1.10 (-2.67%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $40.00 -0.22%
Open$40.65
Prev close$41.19
Day range$39.62 – $41.66
Volume352.2K
Market cap$754.89M
P/E (TTM)2.5
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership103.8%+11.21 pts vs. prior quarter
Institutions holding212+9 vs. prior quarter
Insider trades (recent)26 buys / 22 sellsNet buying
Short interest13.57% of floatDays to cover 12.9 · as of 30 Oct 2026
Short-sale volume share25.3%5-day average of daily volume

Short-sale volume as % of daily volume

12%21%30%39%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$5.11M (13 inflow days, 7 outflow days).

Net flow by order size, last 20 sessions

+$3.8MSuper+$1.3MBig+$1.4MMid+$1.9MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 43.0% of shares outstanding.

Largest holders

  • BlackRock10.97%
  • Soleus Capital Management, L.P.9.79%
  • Armistice Capital LLC8.88%
  • Morgan Stanley Investment Management Inc.6.67%
  • Morgan Stanley6.67%
  • American Century Investment Management5.54%
  • State Street Global Advisors4.67%
  • LSV Asset Management4.18%

By investor type

  • Mutual Fund64.39%
  • Hedge Fund28.52%
  • Public Company8.89%
  • Individual/Insider1.72%
  • Government Pension Fund0.76%
  • Private Company0.46%
  • Bank/Investment Bank0.62%
  • Family Office/Trust0.39%

Reported short interest has fallen from 17.15% to 13.57% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Morgan Stanley Public Company 2026/Q3 +1,070,770 6.7%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +1,070,770 6.7%
Assenagon Asset Management S.A. Mutual Fund 2026/Q3 +535,685 2.8%
American Century Investment Management Mutual Fund 2026/Q3 +302,248 5.5%
BlackRock Mutual Fund 2026/Q3 +125,958 11.0%
LSV Asset Management Mutual Fund 2026/Q3 +65,742 4.2%
UBS Asset Management Mutual Fund 2026/Q3 +52,673 0.9%
Sterling Capital Management LLC Mutual Fund 2026/Q3 +45,329 0.2%
Knights of Columbus Asset Advisors LLC Mutual Fund 2026/Q3 +30,435 0.2%
Martingale Asset Management, L.P. Mutual Fund 2026/Q3 +22,066 0.1%
Soleus Capital Management, L.P. Hedge Fund 2026/Q3 +1,833,504 9.8%
Armistice Capital LLC Hedge Fund 2026/Q3 +392,000 8.9%
American Century Investment Management Mutual Fund 2026/Q3 +197,287 4.0%
Macquarie Investment Management Business Trust Mutual Fund 2026/Q3 +195,000 1.0%
Bridgeway Capital Management, LLC Mutual Fund 2026/Q3 +190,848 1.1%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
1 Sep 2026 Dean Schorno Chief Financial Officer Derivative Exercise and Retained +4,600 $24.20 44,079
31 Aug 2026 Raul Rodriguez Chief Executive Officer Sale to Issuer -2,424 $47.50 179,400
31 Aug 2026 Dean Schorno Chief Financial Officer Sale to Issuer -928 $47.50 44,079
31 Aug 2026 Raymond Furey Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary Sale to Issuer -877 $47.50 14,201
31 Aug 2026 David Santos Executive Vice President Sale to Issuer -874 $47.50 23,320
7 Jul 2026 Alison Hannah Chief Medical Officer Other Acquisition +24,400 – 24,400
21 Jun 2026 Kamil Jackson Independent Director Automatic Disposition -2,500 $35.00 10,125
16 Jun 2026 Raul Rodriguez Chief Executive Officer Other Derivative Acquisition +31,700 $22.49 31,700
16 Jun 2026 Lisa Rojkjaer Former Chief Medical Officer Other Derivative Acquisition +16,769 $22.49 7,394
16 Jun 2026 Dean Schorno Chief Financial Officer Other Derivative Acquisition +7,394 $22.49 7,394
16 Jun 2026 Raymond Furey Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary Other Derivative Acquisition +7,394 $22.49 7,394
16 Jun 2026 David Santos Executive Vice President Other Derivative Acquisition +7,394 $22.49 7,394
31 May 2026 Raul Rodriguez Chief Executive Officer Sale to Issuer -2,424 $29.86 181,138
31 May 2026 Lisa Rojkjaer Former Chief Medical Officer Sale to Issuer -850 $29.86 3,539
31 May 2026 Dean Schorno Chief Financial Officer Derivative Exercise and Sale -928 $29.86 38,187
31 May 2026 Dean Schorno Chief Financial Officer Derivative Exercise and Retained +2,453 $18.70 38,187
31 May 2026 Raymond Furey Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary Sale to Issuer -877 $29.86 12,952
31 May 2026 David Santos Executive Vice President Sale to Issuer -874 $29.86 22,074
25 May 2026 Kamil Jackson Independent Director Automatic Disposition -2,500 $29.17 6,875
14 May 2026 Walter Moos Independent Director Other Acquisition +5,750 – 5,750

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 2,535,665 13.6% 12.9
15 Oct 2026 2,732,739 14.6% 12.8
30 Sep 2026 2,855,433 15.3% 11.1
15 Sep 2026 3,191,811 17.1% 15.8
31 Aug 2026 3,182,110 17.0% 9.1
14 Aug 2026 3,203,364 17.1% 9.8

Discussion

No comments yet — be the first to weigh in on RIGL.

Sign in to join the discussion.

Scroll to Top